MATINAS BIOPHARMA HOLDINGS, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-31.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2017-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2016 was $0.00.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |